.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A Bayesian network meta-analysis published in 2025 compared extended-dose aflibercept 8 mg with faricimab 6 mg using treat-and-extend strategies in diabetic macular edema and neovascular age-related macular degeneration. Across six randomized trials, treatment with aflibercept 8 mg was associated with fewer injections over approximately two years than faricimab treat-and-extend, while absolute changes in best-corrected visual acuity and central subfield thickness did not differ significantly between treatments. Because the analysis was indirect, it should not be interpreted as a head-to-head randomized comparison. Nevertheless, it provides clinically useful context for retina practices trying to balance durability, injection frequency, and visual outcomes. For HCPs, the key message is that extended-interval anti-VEGF therapies can broaden the range of feasible treatment pathways, but drug selection still depends on baseline disease characteristics, response durability, safety considerations, access, cost, and local treatment patterns. Network meta-analysis can help frame these choices, but direct comparative trials remain important when deciding between specific agents.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A Bayesian network meta-analysis published in 2025 compared extended-dose aflibercept 8 mg with faricimab 6 mg using treat-and-extend strategies in diabetic macular edema and neovascular age-related macular degeneration. Across six randomized trials, treatment with aflibercept 8 mg was associated with fewer injections over approximately two years than faricimab treat-and-extend, while absolute changes in best-corrected visual acuity and central subfield thickness did not differ significantly between treatments. Because the analysis was indirect, it should not be interpreted as a head-to-head randomized comparison. Nevertheless, it provides clinically useful context for retina practices trying to balance durability, injection frequency, and visual outcomes. For HCPs, the key message is that extended-interval anti-VEGF therapies can broaden the range of feasible treatment pathways, but drug selection still depends on baseline disease characteristics, response durability, safety considerations, access, cost, and local treatment patterns. Network meta-analysis can help frame these choices, but direct comparative trials remain important when deciding between specific agents.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
